MA54452A - Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a - Google Patents

Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a

Info

Publication number
MA54452A
MA54452A MA054452A MA54452A MA54452A MA 54452 A MA54452 A MA 54452A MA 054452 A MA054452 A MA 054452A MA 54452 A MA54452 A MA 54452A MA 54452 A MA54452 A MA 54452A
Authority
MA
Morocco
Prior art keywords
inhibitors
derivatives used
methionine adenosyltransferase
oxoquinazoline derivatives
oxoquinazoline
Prior art date
Application number
MA054452A
Other languages
English (en)
Inventor
Muzaffar Alam
Leah Cleary
Melissa Fleury
John E Knox
Zachary E R Newby
Zhonghua Pei
Richard Steel
James Sutton
Original Assignee
Ideaya Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ideaya Biosciences Inc filed Critical Ideaya Biosciences Inc
Publication of MA54452A publication Critical patent/MA54452A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA054452A 2018-12-10 2019-12-09 Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a MA54452A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862777715P 2018-12-10 2018-12-10
US201962835853P 2019-04-18 2019-04-18
US201962883945P 2019-08-07 2019-08-07

Publications (1)

Publication Number Publication Date
MA54452A true MA54452A (fr) 2022-03-16

Family

ID=69138003

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054452A MA54452A (fr) 2018-12-10 2019-12-09 Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a

Country Status (17)

Country Link
US (4) US12503467B2 (fr)
EP (1) EP3894396A1 (fr)
JP (2) JP7688578B2 (fr)
KR (1) KR20210103498A (fr)
CN (2) CN119528824A (fr)
AU (1) AU2019395338B2 (fr)
BR (1) BR112021010842A2 (fr)
CA (1) CA3121236A1 (fr)
CL (1) CL2021001508A1 (fr)
CO (1) CO2021008895A2 (fr)
IL (1) IL283743A (fr)
MA (1) MA54452A (fr)
MX (1) MX2021006841A (fr)
PH (1) PH12021551274A1 (fr)
SG (1) SG11202105469YA (fr)
TW (1) TWI863945B (fr)
WO (1) WO2020123395A1 (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020123395A1 (fr) 2018-12-10 2020-06-18 Ideaya Biosciences, Inc. Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a
SG11202108519TA (en) 2019-02-13 2021-09-29 Ptc Therapeutics Inc Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (fr) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Composés de pyrrolo[2,3-d] pyrimidine pour le traitement de la dysautonomie familiale
JP7736700B2 (ja) * 2020-02-28 2025-09-09 リミックス セラピューティクス インコーポレイテッド 複素環アミド及びスプライシングを調節するためのその使用
US20240208965A1 (en) * 2020-06-10 2024-06-27 Ideaya Biosciences, Inc. Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
IL297879A (en) * 2020-06-22 2023-01-01 Hoffmann La Roche Amidopyrimidone derivatives
KR20230026479A (ko) 2020-06-22 2023-02-24 에프. 호프만-라 로슈 아게 설폰 유도체
CN116406271B (zh) * 2020-07-14 2024-09-24 南京再明医药有限公司 双环类化合物
EP4210833A4 (fr) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. Formes cristallines d'un inhibiteur de kras g12c
WO2022063128A1 (fr) * 2020-09-24 2022-03-31 上海凌达生物医药有限公司 Composé de pyridone cyclique ou arylhétérocyclique aromatique, compositions pharmaceutiques et leur utilisation
CA3201663A1 (fr) 2020-11-20 2022-05-27 Amgen Inc. Procede de preparation de 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyridof[2,3-d]pyrimidine-2,4 (1h,3h)-dione
JP2023553492A (ja) * 2020-12-15 2023-12-21 ミラティ セラピューティクス， インコーポレイテッド アザキナゾリン汎ＫＲａｓ阻害剤
EP4262803A4 (fr) 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. Inhibiteurs pan-kras de tétrahydropyridopyrimidine
US20240124454A1 (en) 2020-12-31 2024-04-18 Nanjing Zaiming Pharmaceutical Co., Ltd. Tricyclic compound and use thereof
WO2022206730A1 (fr) * 2021-03-29 2022-10-06 武汉人福创新药物研发中心有限公司 Composé de pyrimidopyrazine et son utilisation
WO2022222911A1 (fr) * 2021-04-19 2022-10-27 武汉人福创新药物研发中心有限公司 Composé pyrimidone et son utilisation
JP2024516429A (ja) * 2021-04-30 2024-04-15 サイノハブ ファーマシューティカル カンパニー リミテッド メチオニンアデノシルトランスフェラーゼ阻害剤、その調製方法およびその適用
WO2022256808A1 (fr) * 2021-06-02 2022-12-08 Ideaya Biosciences Inc. Polythérapie comprenant un inhibiteur de mat2a et un inhibiteur de prmt de type i
EP4347569A4 (fr) * 2021-06-02 2025-03-26 Ideaya Biosciences, Inc. Polythérapie comprenant un inhibiteur de mat2a et un inhibiteur de prmt de type ii
CN117412967A (zh) * 2021-06-02 2024-01-16 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a抑制剂
US12054486B2 (en) 2021-09-24 2024-08-06 Xenon Pharmaceuticals Inc. Pyridine derivatives and their use as sodium channel activators
AR127404A1 (es) * 2021-10-20 2024-01-17 Insilico Medicine Ip Ltd Inhibidores de la metionina adenosiltransferasa 2a (mat2a) y usos de los mismos
CN118265700A (zh) * 2021-11-09 2024-06-28 上海海雁医药科技有限公司 取代的萘啶酮衍生物、其药物组合物及应用
US20250090533A1 (en) * 2021-11-12 2025-03-20 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a taxane
CN118414338A (zh) * 2021-12-21 2024-07-30 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a的杂环抑制剂
JP2025503186A (ja) * 2022-01-26 2025-01-30 勤浩医▲葯▼（▲蘇▼州）有限公司 Ｍｔａｐ欠失型がん治療用メチオニンアデノシルトランスフェラーゼ２ａ阻害剤
WO2023177894A1 (fr) 2022-03-18 2023-09-21 Ideaya Biosciences, Inc. Polythérapie comprenant un inhibiteur de mat2a et un agent antimétabolite
WO2023185811A1 (fr) 2022-03-29 2023-10-05 首药控股(北京)股份有限公司 Nouveau composé hétérocyclique
GB202204913D0 (en) 2022-04-04 2022-05-18 Cambridge Entpr Ltd antiviral therapy
WO2023201338A1 (fr) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Polythérapie comprenant un inhibiteur de mat2a et un inhibiteur de parp
JP2025521737A (ja) 2022-06-27 2025-07-10 石▲薬▼集▲團▼中奇制▲薬▼技▲術▼（石家庄）有限公司 三環式化合物およびその使用
CN117430596A (zh) * 2022-07-13 2024-01-23 上海海和药物研究开发股份有限公司 二并环类mat2a抑制剂及其用途
AU2023361063A1 (en) 2022-10-13 2025-04-17 Hanmi Pharm. Co., Ltd. Novel tricyclic derivative compound and uses thereof
TW202440126A (zh) 2022-11-30 2024-10-16 美商安進公司 利用ｍｔａ協作的ｐｒｍｔ５抑制劑和ｍａｔ２ａ抑制劑之癌症治療
JP2025540086A (ja) * 2022-11-30 2025-12-11 アイディアヤ バイオサイエンシーズ，インコーポレイティド ２－オキソキナゾリン結晶形態
EP4626887A1 (fr) * 2022-11-30 2025-10-08 Ideaya Biosciences, Inc. Atropisomères d'inhibiteurs de mat2a
WO2024118943A2 (fr) * 2022-11-30 2024-06-06 Ideaya Biosciences, Inc. Polythérapie comprenant un inhibiteur de mat2a et un inhibiteur de prmt5
CN116425751B (zh) * 2022-12-19 2024-01-23 艾立康药业股份有限公司 作为mat2a抑制剂的多环类化合物
WO2024217502A1 (fr) * 2023-04-19 2024-10-24 Insilico Medicine Ip Limited Combinaisons d'inhibiteurs de méthionine adénosyltransférase 2a (mat2a) et leurs utilisations
KR20250174628A (ko) * 2023-04-19 2025-12-12 인실리코 메디신 아이피 리미티드 결정성 메티오닌 아데노실트랜스퍼라제 2a (MAT2A) 억제제 및 이의 용도
CN116283800B (zh) * 2023-05-16 2023-07-18 英矽智能科技(上海)有限公司 氧代喹唑啉类化合物及其应用
CN121586715A (zh) * 2023-06-14 2026-02-27 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a杂环抑制剂的盐、晶型及其制备方法
CN116478172B (zh) * 2023-06-20 2023-09-05 英矽智能科技(上海)有限公司 吡咯并[3,2-d]嘧啶类化合物及其应用
WO2025059579A1 (fr) 2023-09-15 2025-03-20 Ideaya Biosciences, Inc. Méthodes de traitement de maladies associées à mat2a
WO2025064750A1 (fr) 2023-09-20 2025-03-27 Ideaya Biosciences, Inc. Polythérapie avec un inhibiteur de parg
WO2025072544A1 (fr) 2023-09-27 2025-04-03 Ideaya Biosciences, Inc. Composés de sulfonamino indazole utilisés en tant qu'inhibiteurs de parg
WO2025166260A1 (fr) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Composés guanidino tricycliques substitués par un amide utilisés en tant qu'inhibiteurs de prmt5
WO2025166215A1 (fr) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Composés guanidino trihétérocycliques utilisés en tant qu'inhibiteurs de prmt5
WO2025166274A1 (fr) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Composés guanidino tricycliques utilisés en tant qu'inhibiteurs de prmt5
WO2025166229A1 (fr) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Composés amidino tricycliques utilisés en tant qu'inhibiteurs de prmt5
WO2025166257A1 (fr) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Composés guanidino trihétérocycliques substitués par un amide utilisés en tant qu'inhibiteurs de prmt5
WO2025223561A1 (fr) * 2024-04-26 2025-10-30 中国科学院上海药物研究所 Composé hétérocyclique à cinq chaînons fusionné à la quinazolinone, composition pharmaceutique associée et utilisation associée
WO2025250569A1 (fr) 2024-05-29 2025-12-04 Amgen Inc. Traitements du cancer utilisant des inhibiteurs de prmt5 mta-coopératifs et des inhibiteurs de mat2a
CN118724899B (zh) * 2024-07-03 2025-09-30 中国药科大学 2(1h)-喹喔啉酮化合物、其药物组合物及应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3202661A (en) 1962-11-27 1965-08-24 Hoffmann La Roche Substituted 3-amino 4-phenyl quinolones
US4096144A (en) 1970-12-08 1978-06-20 Sumitomo Chemical Company, Limited Process for preparing quinazolinone derivatives and their 2-(N-mono-substituted amino)-phenyl ketone intermediate derivatives
JPS5761758B2 (fr) 1974-01-11 1982-12-25 Hisamitsu Pharmaceutical Co
WO1994007498A1 (fr) 1992-10-07 1994-04-14 Sumitomo Pharmaceuticals Company, Limited Composition pharmaceutique utilisee pour inhiber la production des facteurs de necrose tumorale
EP0759454B1 (fr) 1994-05-11 2002-03-06 Asahi Kasei Kabushiki Kaisha Piece moulee en polyamide aromatique para-oriente, et procede de production d'une telle piece
US5525711A (en) * 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
NZ322197A (en) 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
TW504504B (en) 1996-11-26 2002-10-01 Bristol Myers Squibb Co 4-aryl-3-hydroxyquinolin-2-one derivatives as ion channel modulators
AU742452B2 (en) 1997-08-28 2002-01-03 Bristol-Myers Squibb Company 4-aryl-3-aminoquinoline-2-one derivatives as potassium channel modulators
PA8539401A1 (es) 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
AR038658A1 (es) 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
WO2004065542A2 (fr) 2002-12-30 2004-08-05 Exelixis, Inc. Mat2a utilises comme modificateurs de la voie p53 et procedes d'utilisation
WO2005020885A2 (fr) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions et methodes pour le traitement du syndrome respiratoire aigu severe (sras)
US7049309B2 (en) 2003-10-14 2006-05-23 Bristol-Myers Squibb Company 3-Thia-4-arylquinolin-2-one potassium channel modulators
US8338435B2 (en) 2006-07-20 2012-12-25 Gilead Sciences, Inc. Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
RU2477046C2 (ru) 2006-11-22 2013-03-10 Сумитомо Кемикал Компани, Лимитед Агент для ингибирования сигнальной функции цитокинина
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
EP2266984A1 (fr) 2009-06-26 2010-12-29 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Pyrido[2,3-d]pyrimidines en tant qu' antagoniste du Wnt pour le traitement du cancer et de l'arthrite
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
EP4166558A1 (fr) 2010-02-12 2023-04-19 Pfizer Inc. Sels et polymorphes de 8-fluoro-2-{4-[(méthylamino} méthyl] phényl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one
PT2611797T (pt) * 2010-08-31 2017-02-07 Hanmi Science Co Ltd Derivados de quinolina ou de quinazolina com atividade indutora de apoptose nas células
CN110015962B (zh) 2011-01-28 2022-03-15 肯塔基大学研究基金会 茋类似物和治疗癌症的方法
JP2014519340A (ja) 2011-06-16 2014-08-14 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． バイオマーカー組成物および方法
CN103842364A (zh) 2011-09-30 2014-06-04 奇尼塔公司 抗病毒化合物
CN104011050A (zh) * 2011-12-22 2014-08-27 霍夫曼-拉罗奇有限公司 作为丝氨酸/苏氨酸激酶抑制剂的2,4-二氨基-嘧啶衍生物
CN102816197B (zh) 2012-08-24 2015-04-29 四川大学华西医院 一种新的嘧啶并嘧啶类核苷类似物、制备方法及其形成的超分子结构和应用
EA201591746A1 (ru) 2013-03-14 2016-08-31 КОНВЕРДЖЕН ЭлЭлСи Способы и композиции для ингибирования бромодомен-содержащих белков
WO2017096165A1 (fr) 2015-12-03 2017-06-08 Agios Pharmaceuticals, Inc. Inhibiteurs de mat2a pour le traitement du cancer n'exprimant pas mtap
KR102470130B1 (ko) 2016-07-18 2022-11-24 내셔널 인스티튜트 오브 바이올로지칼 사이언시스, 베이징 아폽토시스 억제제
JP6832430B2 (ja) 2016-08-31 2021-02-24 アジオス ファーマシューティカルズ， インコーポレイテッド 細胞代謝過程の阻害剤
WO2018039772A1 (fr) 2016-09-02 2018-03-08 FutureVault Inc. Systèmes et procédés de filtrage de documents en temps réel
CN110366550A (zh) 2016-12-22 2019-10-22 美国安进公司 作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物
AU2018273356B2 (en) 2017-05-22 2021-09-16 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US11161839B2 (en) * 2017-05-26 2021-11-02 The Institute Of Cancer Research: Royal Cancer Hospital 2-quinolone derived inhibitors of BCL6
WO2018221433A1 (fr) 2017-05-29 2018-12-06 第一三共株式会社 Dérivé d'amine hétéroaryle
AU2018329920B2 (en) 2017-09-08 2022-12-01 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
US11524960B2 (en) 2018-03-30 2022-12-13 Servier Pharmaceuticals Llc Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
CA3098574A1 (fr) 2018-05-04 2019-11-07 Amgen Inc. Inhibiteurs de kras g12c et leurs procedes d'utilisation
US11285156B2 (en) 2018-06-12 2022-03-29 Amgen Inc. Substituted piperazines as KRAS G12C inhibitors
GB2575490A (en) 2018-07-12 2020-01-15 Recordati Ind Chimica E Farmaceutica Spa P2X3 receptor antagonists
US11376256B2 (en) 2018-07-19 2022-07-05 Agency For Science, Technology And Research Method of treating a methionine-dependent cancer
EP3887373A1 (fr) 2018-11-29 2021-10-06 Araxes Pharma LLC Composés et procédés d'utilisation associés pour le traitement du cancer
WO2020123395A1 (fr) 2018-12-10 2020-06-18 Ideaya Biosciences, Inc. Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a
LT3902803T (lt) 2018-12-27 2023-04-25 Les Laboratoires Servier Aza-heterobicikliniai mat2a inhibitoriai ir būdai, skirti panaudoti vėžio gydymui
EA202191800A1 (ru) 2018-12-27 2021-09-13 Ле Лаборатуар Сервье Сас Азагетеробициклические ингибиторы мат2а и способы их применения для нацеливания на рак
US20240208965A1 (en) 2020-06-10 2024-06-27 Ideaya Biosciences, Inc. Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
WO2021252680A1 (fr) 2020-06-10 2021-12-16 Ideaya Biosciences, Inc. Dérivés de 4-arylquinazoline en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a
EP4165040B1 (fr) 2020-06-10 2025-08-27 Ideaya Biosciences, Inc. Dérivés de 2-aminoquinazolinone comme inhibiteurs de la méthionine adénosyltransférase 2a
US20230227409A1 (en) 2020-06-10 2023-07-20 Ideaya Biosciences, Inc. Quinolinone derivatives as methionine adenosyltransferase 2a inhibitors
TW202227082A (zh) 2020-08-12 2022-07-16 美商施維雅製藥有限公司 用於治療癌症之組合療法
WO2022053908A1 (fr) 2020-09-11 2022-03-17 株式会社半導体エネルギー研究所 Dispositif d'affichage, module d'affichage et appareil électronique
EP4347569A4 (fr) 2021-06-02 2025-03-26 Ideaya Biosciences, Inc. Polythérapie comprenant un inhibiteur de mat2a et un inhibiteur de prmt de type ii
US20250090533A1 (en) 2021-11-12 2025-03-20 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a taxane
WO2023196985A1 (fr) 2022-04-08 2023-10-12 Ideaya Biosciences, Inc. Inhibiteurs de méthionine adénosyltransférase 2a
WO2023201338A1 (fr) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Polythérapie comprenant un inhibiteur de mat2a et un inhibiteur de parp
EP4626887A1 (fr) 2022-11-30 2025-10-08 Ideaya Biosciences, Inc. Atropisomères d'inhibiteurs de mat2a

Also Published As

Publication number Publication date
AU2019395338A1 (en) 2021-07-29
PH12021551274A1 (en) 2021-12-06
KR20210103498A (ko) 2021-08-23
MX2021006841A (es) 2021-07-02
TWI863945B (zh) 2024-12-01
US20220106276A1 (en) 2022-04-07
BR112021010842A2 (pt) 2021-08-24
CN119528824A (zh) 2025-02-28
CL2021001508A1 (es) 2022-01-21
US11130759B1 (en) 2021-09-28
US12503467B2 (en) 2025-12-23
JP2025116052A (ja) 2025-08-07
CO2021008895A2 (es) 2021-07-30
JP7688578B2 (ja) 2025-06-04
CN113166078A (zh) 2021-07-23
AU2019395338B2 (en) 2025-11-13
WO2020123395A1 (fr) 2020-06-18
CA3121236A1 (fr) 2020-06-18
US11084798B1 (en) 2021-08-10
CN113166078B (zh) 2024-11-19
JP2022512156A (ja) 2022-02-02
EP3894396A1 (fr) 2021-10-20
US11046691B1 (en) 2021-06-29
SG11202105469YA (en) 2021-06-29
TW202039487A (zh) 2020-11-01
IL283743A (en) 2021-07-29

Similar Documents

Publication Publication Date Title
MA54452A (fr) Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a
MA51610A (fr) Dérivés d'imidazole fusionnés utilisés en tant qu'inhibiteurs d'il-17
MA54076A (fr) 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
EP3873468A4 (fr) 2-amino-n-phényl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
EP3784665A4 (fr) Dérivés de pyridazine en tant qu'agents de dégradation de smarca2/4
EP3733671A4 (fr) Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase
EP3853220A4 (fr) Dérivés de quinazoline en tant qu'agents antitumoraux
EP3768671A4 (fr) Dérivés d'imidazolidine-2-one substitués en tant qu'inhibiteurs de prmt5
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
EP3733673A4 (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
EP3687543A4 (fr) Agents pharmaceutiques en combinaison en tant qu'inhibiteurs de rsv
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
MA54157A (fr) Dérivés de spiro-sulfonamide en tant qu'inhibiteurs de la protéine de la leucémie myéloïde -1 (mcl-1)
EP3941525A4 (fr) Dérivés de benzodiazépine en tant qu'inhibiteurs de rsv
MA48987A (fr) Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA49888A (fr) Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
MA48943A (fr) Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA44498A (fr) Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA45153A (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA44502A (fr) Dérivés d'indole substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
EP3487839A4 (fr) Dérivés d'amide utilisés en tant que bloqueurs de nav1,7 et de nav1,8
MA49128A (fr) Dérivés de pyrimidine utilisés en tant que modulateurs des récepteurs des pge2